Paul Richardson, MD Dana Farber Cancer Institute Interview Date: August 3, 2018 Summary Myeloma research is moving quickly, with more treatment approaches being developed by researchers. Dr. Paul Richardson shares a mid-year myeloma update to catch us up and provides a treatment overview for early precursor condition myeloma and for newly diagnosed and relapsed/refractory patients.[...]

Brian McMahon SparkCures Interview Date: July 30, 2018 Summary Why and when should multiple myeloma patients join clinical trials? Brian McMahon of SparkCures shares three steps patients can take to participate in clinical trials: awareness, understanding and action. SparkCures is a clinical trial finder tool specifically for multiple myeloma patients and can help you find[...]

Muhamed Baljevic, MD University of Nebraska Interview Date: May 28, 2018     Many patients’ myeloma can become resistant to an important class of drugs use for myeloma care – proteasome inhibitors. Most patients (70%) will respond to these drugs as single therapies but some patients can be resistant initially. Researchers at MD Anderson Cancer[...]

Rafael Fonseca, MD Mayo Clinic Scottsdale Interview Date: May 18, 2018 Summary Dr. Rafael Fonseca joins Myeloma Crowd Radio to share a new tool for myeloma patients called HealthTree. HealthTree can help myeloma patients find and understand personally relevant treatment options that can then be taken to their doctor for an informed clinic visit. HealthTree[...]

[...]

[...]

[...]

    Martin Kaiser, MD Institute of Cancer Research Interview Date: February 5, 2018   Summary Martin Kaiser, MD of the Institute of Cancer Research in the United Kingdom joins Myeloma Crowd Radio at ASH 2017 to discuss myeloma care in the United Kingdom and how the aggregation of myeloma genomic data from over 4,000[...]

Robert Z. Orlowski, MD MD Anderson Cancer Center Interview Date: January 5, 2018 Summary Much is happening in the world of myeloma. Where are we headed in 2018? Dr. Robert Z. Orlowski of the MD Anderson Cancer Center joins us to share the latest. He reviews a variety of treatment options for smoldering myeloma, emphasizes[...]

Irene Ghobrial, MD Dana Farber Cancer Institute Interview Date: September 27, 2017 Summary Myeloma patients hate the bone marrow biopsy, which can determine the level of tumor burden as well as the genetics of myeloma. These biopsies are a literal pain in the butt for patients who see them as a necessity to gain information[...]